NCT02065986View on ClinicalTrials.gov

Pre-exposure Option for Reducing HIV in the UK.(PROUD)

PHASE4CompletedINTERVENTIONAL
Enrollment

544

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

November 30, 2014

Study Completion Date

October 31, 2016

Conditions
HIV
Interventions
DRUG

Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)

Trial Locations (1)

WC2B 6NH

MRC Clinical Trials Unit, London

All Listed Sponsors
lead

MRC [ycm]

OTHER_GOV

NCT02065986 - Pre-exposure Option for Reducing HIV in the UK.(PROUD) | Biotech Hunter | Biotech Hunter